HOKKAIDO UNIVERSITY

Title	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy : final results of the randomized GO-FORTH trial
Author(s)	Tanaka, Yoshiya; Harigai, Masayoshi; Takeuchi, Tsutomu et al.
Citation	Modern Rheumatology, 26(4), 481-490 https://doi.org/10.3109/14397595.2015.1109762
Issue Date	2016
Doc URL	https://hdl.handle.net/2115/62847
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/3.0/
Type	journal article
File Information	imor_a_1109762_sm9295.pdf, Supplemental Table

Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP

Supplemental Table 1. Baseline characteristics for progressors and nonprogressors at week 104.

	Golimumab 50 mg + MTX		Golimumab 100 mg + MTX	
Baseline characteristics	Patients with change in total vdH-S ≥ 3 (n=54)	Patients with change in total vdH-S < 3 (n=13)	Patients with change in total vdH-S ≥ 3 (n=57)	Patients with change in total vdH-S < 3 (n=14)
Disease duration, years	9.5 (9.4)	3.8 (3.5)*	8.1 (6.5)	6.0 (5.2)
DAS28-ESR	5.2 (1.1)	6.4 (0.7)*	5.4 (1.0)	5.8 (1.0)
TJC	12.2 (7.8)	16.4 (8.6)	12.9 (7.3)	15.1 (10.5)
SJC	10.4 (5.9)	15.9 (6.6)*	11.2 (6.4)	13.9 (7.6)
HAQ-DI	0.9 (0.6)	1.1 (0.6)	1.0 (0.6)	1.0 (0.6)
CRP	1.2 (1.2)	3.4 (3.0)*	1.3 (1.4)	2.6 (2.4)*
vdH-S	54.2 (62.0)	42.6 (45.7)	53.7 (49.8)	41.8 (33.0)
Annual rate of radiographic progression[a]	6.7 (6.7)	11.1 (6.5)*	7.4 (5.6)	12.3 (14.0)*

Data presented as mean (SD). [a]vdH-S/disease duration *p<0.05

CRP, C-reactive protein; DAS28-ESR, 28-joint count Disease Activity Score using erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; SJC, swollen joint count; TJC, tender joint count; vdH-S score, van der Heijde modification of the Sharp score